Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials

被引：3

作者：

Blauvelt, Andrew ^{[11
]}

Armstrong, April ^{[1
]}

Merola, Joseph F. ^{[2
]}

Strober, Bruce ^{[3
,4
,5
]}

de Cuyper, Dirk ^{[6
]}

Peterson, Luke ^{[7
]}

Davies, Owen ^{[8
]}

Stark, Jeffrey L. ^{[9
]}

Lebwohl, Mark ^{[10
]}

机构：

[1] Oregon Med Res Ctr, Portland, OR USA

[2] Univ Calif Los Angeles UCLA, Los Angeles, CA USA

[3] UT Southwestern Med Ctr, Div Rheumatol, Dept Dermatol, Dallas, TX USA

[4] UT Southwestern Med Ctr, Dept Med, Div Rheumatol, Dallas, TX USA

[5] Yale Univ, Dept Dermatol, New Haven, CT USA

[6] Cent Connecticut Dermatol Res, Cromwell, CT USA

[7] UCB Pharm, Brussels, Belgium

[8] UCB Pharm, Morrisville, NC USA

[9] UCB Pharm, Slough, England

[10] UCB Pharm, Smyrna, GA USA

[11] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2024年 / 91卷 / 01期

关键词：

bimekizumab; clinical trial; depression; eC-SSRS; long-term; mental health; PHQ-9; plaque; SEVERE PLAQUE PSORIASIS; DOUBLE-BLIND; MULTICENTER; BRODALUMAB; DEPRESSION; USTEKINUMAB; SUICIDALITY; EFFICACY; VALIDITY; ANXIETY;

D O I：

10.1016/j.jaad.2024.02.039

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background: Patients with psoriasis have increased risk of suicidal ideation and behavior (SIB) and depression. Bimekizumab, a biologic that inhibits interleukin (IL)-17A and IL-17F, received Food and Drug Administration approval in 2023 for moderate to severe plaque psoriasis, following 2021 European Medicines Agency approval. Objective: To report SIB and depression in patients with moderate to severe psoriasis treated in bimekizumab clinical trials. Methods: Mental health changes, including neuropsychiatric events, were actively monitored across 9 bimekizumab clinical trials in psoriasis phase 2/3 trials. The patient-reported electronic Columbia-Suicide Severity Rating Scale (measuring SIB) and Patient Health Questionnaire-9 (measuring depression) were administered, monitored by an independent Neuropsychiatric Adjudication Committee. Results: Throughout 7166 patient-years (PY) of bimekizumab exposure, the adjudicated SIB rate was 0.13/ 100PY; SIB ranges for the general psoriasis population and patients receiving anti-IL-17A/anti-IL-23

引用

页码：72 / 81

页数：10

共 56 条

[1] Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F [J].

Adams, Ralph ;

Maroof, Asher ;

Baker, Terry ;

Lawson, Alastair D. G. ;

Oliver, Ruth ;

Paveley, Ross ;

Rapecki, Steve ;

Shaw, Stevan ;

Vajjah, Pavan ;

West, Shauna ;

Griffiths, Meryn .

FRONTIERS IN IMMUNOLOGY, 2020, 11

[2] Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial [J].

Armstrong, April W. ;

Gooderham, Melinda ;

Warren, Richard B. ;

Papp, Kim A. ;

Strober, Bruce ;

Thaci, Diamant ;

Morita, Akimichi ;

Szepietowski, Jacek C. ;

Imafuku, Shinichi ;

Colston, Elizabeth ;

Throup, John ;

Kundu, Sudeep ;

Schoenfeld, Steve ;

Linaberry, Misti ;

Banerjee, Subhashis ;

Blauvelt, Andrew .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 88 (01) :29-39

[3] Quality of life in psoriasis patients [J].

Augustin, Matthias ;

Radtke, Marc Alexander .

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (04) :559-568

[4]

Australian Government Department of Health and Aged Care, 2022, Australian prescription medicine decision summaries: Bimzelx

[5] Meta-Analysis of Cytokines and Chemokines in Suicidality: Distinguishing Suicidal Versus Nonsuicidal Patients [J].

Black, Carmen ;

Miller, Brian J. .

BIOLOGICAL PSYCHIATRY, 2015, 78 (01) :28-37

[6] Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study [J].

Blauvelt, Andrew ;

Papp, Kim A. ;

Merola, Joseph F. ;

Gottlieb, Alice B. ;

Cross, Nancy ;

Madden, Cynthia ;

Wang, Maggie ;

Cioffi, Christopher ;

Griffiths, Christopher E. M. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (05) :1367-1374

[7] The role of inflammation in suicidal behaviour [J].

Brundin, L. ;

Erhardt, S. ;

Bryleva, E. Y. ;

Achtyes, E. D. ;

Postolache, T. T. .

ACTA PSYCHIATRICA SCANDINAVICA, 2015, 132 (03) :192-203

[8]

ClinicalTrials.gov, 2017, A study to evaluate the long-term safety, tolerability and efficacy of bimekizumab in adult patients with chronic plaque psoriasis (PS0018)

[9] The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries [J].

Dalgard, Florence J. ;

Gieler, Uwe ;

Tomas-Aragones, Lucia ;

Lien, Lars ;

Poot, Francoise ;

Jemec, Gregor B. E. ;

Misery, Laurent ;

Szabo, Csanad ;

Linder, Dennis ;

Sampogna, Francesca ;

Evers, Andrea W. M. ;

Halvorsen, Jon Anders ;

Balieva, Flora ;

Szepietowski, Jacek ;

Romanov, Dmitry ;

Marron, Servando E. ;

Altunay, Ilknur K. ;

Finlay, Andrew Y. ;

Salek, Sam S. ;

Kupfer, Joerg .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 (04) :984-991

[10]

Drug and Health Product Register (Canada), 2022, Bimzelx product monograph

← 1 2 3 4 5 6 →